Gilead Sciences (B) Implementing the Gilead Access Program for HIV Drugs

Gilead Sciences (B) Implementing the Gilead Access Program for HIV Drugs

By
David Baron, Keith Krehbiel, Brian Tayan
2007|Case No.P53B

This case describes Gilead Sciences’ initial experience implementing an access program for delivering its AIDS drug Viread to developing nations in Africa. In April 2003 Gilead announced the Gilead Access Program to make available the company’s new drug Viread at no profit to developing countries. Viread represented a significant advancement in antiretroviral medicines for the treatment of HIV/AIDS with once-a-day dosage, greater effectiveness, and a much improved side-effect profile. Gilead executives expected the Access Program to have an immediate, positive impact on the treatment of HIV/AIDS patients in the world’s poorest countries. A year after implementation, however, the Access Program had not led to widespread use of Viread in Africa. Having learned from early missteps, Gilead had to make significant changes to improve the program. It also wanted to expand the Access Program to create greater access to therapies in middle-income regions. Readers of the case are asked to address these issues. The A case discusses Gilead’s initial considerations in designing the Access Program.

Learning Objective
This material is available for download by current Stanford GSB students, faculty, and staff, as well as Stanford GSB alumni. For inquiries, contact the Case Writing Office.

Available for Purchase